Instrument Inactif

Communiqués Biocartis Group NV

Actions

BCART

BE0974281132

Equipement, fournitures et distribution médicale

PEA

PEA/PME

Communiqués

11/03	Biocartis Receives European IVDR Certification for the Idylla CDx MSI Test	AQ
08/01	Biocartis : Corporate Event Notice 8Jan2026	PU
18/12	BIOCARTIS : ANNOUNCES JUDICIAL DISSOLUTION AND APPOINTMENT OF A LIQUIDATOR	PU
18/12	BIOCARTIS : KONDIGT GERECHTELIJKE ONTBINDING EN AANSTELLING VAN EEN VEREFFENAAR AAN	PU
26/08/25	Biocartis : RESULTS OF THE ANNUAL GENERAL SHAREHOLDERS' MEETING HELD ON 25 AUGUST 2025	PU
18/08/25	Biocartis : Welcomes Mike Kreitzinger as Senior Vice President of Global Business Development	PU
28/07/25	Biocartis : Algemene vergadering	PU
28/07/25	Biocartis : General meeting	PU
03/04/25	Biocartis Announces Launch of the Brand-New Idylla POLE-POLD1 Mutation Assay	AQ
18/03/25	Biocartis : Announces Multiple Abstracts Demonstrating the Impact of Idylla™ in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting	PU
17/02/25	Biocartis announces new data on early CAR-T vector load assessment with Idylla presented at ASTCT, A Potential Breakthrough in LBCL Treatment Monitoring	AQ
14/02/25	Biocartis announces new data on early CAR-T vector load assessment with Idylla presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring	PU
23/10/24	Biocartis : announces six Idylla™ abstracts to be presented at AMP 2024 Annual Meeting	PU
09/05/24	Press release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meeting	GL
10/01/24	Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of major shareholdings)	GL
10/01/24	Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)	GL
10/01/24	Press release Biocartis Group NV: Disclosure of transparency notification (Article 14, first paragraph, of the Act of 2 May 2007 on the disclosure of large shareholdings)	AQ
22/11/23	Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion	GL
13/11/23	Press release Biocartis NV: Biocartis Hosts Corporate Workshop and Announces Seven Idylla™ Abstracts to be Presented at AMP 2023 Annual Meeting	GL
31/10/23	Press release Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors	GL
20/10/23	Press release Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla™ Presented at European Society of Molecular Oncology Congress (ESMO)	GL
16/10/23	Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio	AQ
16/10/23	Press release Biocartis Group NV: Biocartis Honors Breast Cancer Awareness Month with Launch of Breast Cancer Portfolio	GL
12/10/23	Press release Biocartis Group NV: Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies to Commercialize the APIS ESR1 Mutations Kit	GL
03/10/23	Press Release Biocartis Group NV: Disclosure of transparency notification	GL